BIOSTEM TECHNOLOGIES - Key Persons

Job Titles:

• Member of the Board of Directors
• Member of the Management Team

Job Titles:

• Member of the Board of Directors
• Chairman of Audit Committee and Board Member

Mr. Poe is a veteran executive with more than 25 years of financial experience across various industries, including life sciences, medical devices and healthcare services. He currently serves as Chief Financial Officer (CFO) of Midi Health, a leader in women's healthcare. Previously, he served as CFO of Jumpcode Genomics, a genomic tools company unlocking the power of next-generation sequencing using CRISPRclean technology and CFO at Genome Medical, a genomic telehealth provider, where he led all aspects of finance at both companies. Mr. Poe has also held the positions of Vice President of Finance at Illumina, the leader in genomics technology; CFO at Sotera Wireless, a medical device start-up; and Vice President of Finance at Inverness Medical Innovations, a point-of-care diagnostics company acquired by Abbott. Mr. Poe received his bachelor's degree from Bucknell University and his MBA from the University of Chicago Booth School of Business

Job Titles:

• Member of the Board
• Member of the Scientific Advisory Board

Daniel Shelly, Ph.D., MBA is Vice President of Business Development and Alliances at Prescient Therapeutics. At Prescient, he is responsible for advancing the development of a next-generation Chimeric Antigen Receptor T and or NK Cell therapy technology along with small molecule targeted therapies. Prior to Prescient, he was Director of Global Business Development and Strategic Partnerships for the Global non-profit organization PATH where he was involved in the identification of new and innovative partnerships for vaccine and therapeutics development applicable to low and middle-income countries. He has an additional 18 years of industry experience having worked for Albumedix, Novozymes Biopharma, Meridian Life Science, and Kendle International. He has been responsible for asset in-licensing, alliances, and out-licensing of core drug delivery technologies along with biologics manufacturing, proposal writing, contract negotiations, market assessments, and clinical development/out-licensing of several vaccines. Dr. Shelly is also an adjunct professor in the Masters in Clinical Drug Development program at the UC College of Pharmacy. He has a B.S. in Animal Behavior from Lehigh University, a MA in Comparative Physiology from College of William and Mary, a Ph.D. in Molecular Physiology from Florida State University, and an MBA in Management of Advanced Technology and Innovation from the University of Cincinnati.

Dr. Weston's research career began in California with studies on muscle regeneration following spinal cord injury and muscle development in sub-ideal conditions (e.g., space flight). She then began working on bone regeneration at Loma Linda VA. Dr. Weston relocated to Florida to investigate hematopoietic stem cell characteristics and self-renewal in response to micro-environmental factors. Here, she earned her PhD in Molecular Cell and Developmental Biology. Interest in stem cell microenvironments led to studies at Miami VA on the healing effect of mesenchymal stem cell (MSC) exosome and growth factor delivery. Successes in MSC work expanded her interest in the mechanisms of allograft healing in healthy and damaged environments. She was recruited to the biotech sector by Vivex Biomedical for work at the University of Miami Tissue Bank where Dr. Weston's innovation and leadership in product development resulted in highly effective products and multiple patents. She was offered the opportunity to continue her research at the very impressive, well-equipped Cell Therapy Institute at Nova Southeastern University. This allowed her to expand to the evaluation of microvesicles in sarcoma initiation and progression for the purpose of biomarker elucidation. While at NSU, she served the Medical School (NSU MD) on the Curriculum Committee, Pre-clerkship Committee and as the Genomics Thread Director. Her consulting activities in the biotechnology space resulted in strong and prosperous relationships with several companies where she has enjoyed the development and characterization of products for market use. As a member of the American Association of Tissue Banks and a Certified Tissue Bank Specialist, she has served as Vice Chair of Bylaws and Ethics and sits on the Living Donor Council. She has presented internationally and serves as a reviewer for several publications. To date, Dr. Weston has 14 granted patents. Currently, Dr. Weston is Vice President of Research and Development for Biostem Technologies. In this role, she is optimizing the regenerative and healing capacity of birth tissues in various tissue microenvironments and has submitted more patents on this subject. She has fueled the development of some new products and facilitated the optimization of others, intent on honoring the Gift of birth tissue and healing those in dire need by producing the most effective, safe products possible.

Job Titles:

• Chief Executive Officer
• Member of the Board of Directors
• Member of the Management Team

Jason Matuszewski brings a wealth of experience in strategic operations planning and technical projects management from his rigorous technical background. His diverse expertise includes continuous process improvement, training and development programs, regulatory compliance and best practices implementation, and advanced problem solving. He began his career as a technical engineer working for Adecco at SC Johnson in 2009, where he developed comprehensive maintenance plans to support manufacturing processes at scale. He then transitioned to manufacturing and quality engineering for major organizations, including ATI Ladish Forging, Nemak, and HUSCO International, where he spearheaded process design and implementation, solved complex supply-chain and manufacturing problems, and improved product sourcing and purchasing. His philanthropic work with the Juvenile Diabetes Research Foundation sparked an interest in biotech, leading him to co-found Biostem Technologies in 2014. As CEO he has leveraged his expertise to optimize tissue sourcing, strategically build out a 6,000 square foot tissue processing facility that is fully compliant with FDA 210, 211, 1271, and AATB standards, and put together an expert team of professionals to support the company's continued growth. Jason holds a B.S. in Mechanical Engineering Technology and a minor in Mathematics from the Milwaukee School of Engineering and is Six Sigma Black Belt certified. He also serves as a Processing and Distribution Council Member for the American Association of Tissue Banks (AATB), as well as serves as a member of the Government Affairs committee for BioFlorida.

Job Titles:

• Member of the Board
• Member of the Scientific Advisory Board
• Professor of Pharmacology & Therapeutics

Jeffrey K. Harrison, Ph.D. is a Professor of Pharmacology & Therapeutics in the College of Medicine at the University of Florida. He directs an NIH-funded pre-clinical/translational research lab that seeks to better understand the role of chemokines and immune cells in the progression of brain tumors and their resistance to immunotherapies. He has collaborated with numerous pharmaceutical companies, large and small, to evaluate novel therapeutic agents in pre-clinical models of glioma. He also provides formal teaching to the next generation of scientists about the process by which novel small molecules and biologic agents are evaluated in preclinical studies that are aimed toward taking these therapeutics into first-in-human clinical trials. He holds a B.S in Cellular & Molecular Biology and a Ph.D. in Pharmacology from the University of Michigan.

Job Titles:

• Chairman of the Board
• Member of the Scientific Advisory Board
• Board and Audit Committee Member

Kenneth Warrington, Ph.D., has decades of broad expertise across the cell and gene therapy product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling pre-clinical and early-stage clinical programs. He has deep knowledge in advanced therapy manufacturing, including live attenuated and virus-like particle vaccines, live challenge viruses, viral vectors, and cell & gene-modified cell therapies. He served on the faculty at the University of Florida, Pediatrics-Division of Cellular & Molecular Therapy, with a research program focused on AAV vector development and production. Following his transition into industry in 2008, Dr. Warrington has held the lead technical operation and business development roles for global contract testing and manufacturing organizations, including Meridian Life Science, SGS Life Science, and Wuxi Apptec. He was formerly the SVP of Operations and Business Development at Biostem Life Sciences before assuming the role of chairman of the scientific advisory board. Dr. Warrington is currently Head of Strategy & Innovation and a Sr. Director of Business Development at GenScript ProBio, leading their gene & cell therapy CMC services, and Chief Technology Officer at Lacerta Therapeutics. He holds a B.S. in Biology & Chemistry from St. Lawrence University and a Ph.D. in Pharmacology & Experimental Therapeutics from the University of Florida.

Job Titles:

• Chief Financial Officer

Michael Fortunato spent 11 years at "Big 4" accounting firms having served clients within the health and life sciences industries. He spent almost seven years with the SEC's Enforcement Division, San Francisco Regional Office where he monitored SEC registrant compliance with SEC rules and regulations for companies located from Northern California to Washington State. Mr. Fortunato also held various technical accounting and SEC reporting roles with major technology companies located within the SF Bay Area. He has participated in six IPOs including Alibaba's $22 billion initial public offering. Mr. Fortunato holds a B.S. in accounting from Rutgers University and holds an active CPA license in the State of Florida.

Job Titles:

• Vice President of Marketing

Neal Bhattacharya has over 21 years of experience in marketing, strategic and tactical brand planning and product development. Focusing his career on marketing products in health-related categories, Neal has successfully developed, commercialized and grown over 200 products, spanning both consumer packaged goods and medical device SKUs. Before BioStem Technologies, he spent fourteen years of his career at Trividia Health, Inc., developing and marketing products to healthcare professionals and consumers with diabetes, providing high-quality, high-value products to improve patient's lives. Prior to that, Neal honed his marketing skills in multiple global companies including Covidien, Novartis, Rexall Sundown and Kimberly-Clark. Mr. Bhattacharya holds an MBA from the Krannert School of Management - Purdue University, an M.A. in biology from Washington University, and a B.S. in biology from Emory University.

Job Titles:

• Chairman of the Comp Committee. Board and Audit Committee Member

Mr. Daly is an award-winning executive leader with over thirty-five years of experience and a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. Mr. Daly serves as the Global VP MedTech Data Delivery and previously served as Global VP Commercial Solutions at IQVIA Holdings, where he was responsible for leading a global strategic MedTech Commercial Solutions business unit. Prior to that, he held the position of President and CEO at Cohera Medical, an early-stage commercial-stage life sciences company developing biomaterials for surgical adhesives, sealants, and drug delivery products that was acquired by global investment firm, KKR. At Cohera, Mr. Daly spearheaded the development of a novel delivery device for synthetic surgical adhesive that maintained a two-year shelf life and received the Businesswire 2012 Medical Design Excellence Award. Mr. Daly also held leadership positions for more than a decade at Johnson & Johnson.

Job Titles:

• Member of the Board
• Member of the Scientific Advisory Board
• Healthcare Executive

Shaun Opie, Ph.D. is a healthcare executive and has co-founded several laboratories in multiple disciplines including cardiac stem cell transplantation, clinical diagnostics, and cannabis safety testing. Before pursuing his entrepreneurial interests, he was a clinical trial administrator at Banner Health and oversaw an active, multi-site, sponsored clinical research program providing support for investigational new drugs, devices, and biologics, as well as tissue collection/biobanking and medical education research. He has held multiple adjunct faculty appointments at Arizona State University in the College of Health Solutions and also spent 2 years as an invited Entrepreneurship Expert at the W.P. Carey School of Business. Dr. Opie has a proven public-speaking track record and is an author of numerous scientific publications and textbooks. He has a BS in Biology from Bucknell University and a Ph.D. in Molecular Genetics/Virology from the University of Florida.

Job Titles:

• Chief Commercial Officer

Job Titles:

• Chairman of the Board

Tom Dugan is a proven, hands-on senior executive who has transformed businesses, established new market opportunities, and driven growth in the face of strong competition. He co-founded 360 Life Sciences Advisors working with private equity and venture capital firms to assess new investment opportunities and improve performance at portfolio companies. Most recently, Tom was the President of Integrum, Inc., the pioneer in osseointegrated orthopedic implants that improve the lives of those with limb loss. Previously, he held multiple leadership positions including Chief Executive Officer at Amniox Medical, a pioneer in amniotic membrane products for wound care and surgical applications, President at SurgiQuest, Inc., President of the Americas for Smith and Nephew Wound Management, and served in senior roles at SonoSite, Rita Medical Systems and Tyco Healthcare. Tom served on the board of directors of Rita Medical Systems (NASDAQ: RITA), which was acquired byAngioDynamics, and various venture-backed medical device companies. He chaired the Wound Healing and Tissue Regeneration sector of AdvaMed and served on the board of MITA, the industry trade group for medical imaging.